After taking up residency at the star-studded Boston accelerator Petri, Burger’s startup — named New Equilibrium Biosciences — has scored $10 million in seed cash from the VC firm to prove that by reaching into those corners, they could uncover drugs against “Holy Grail” targets in everything from cancer to neurodegenerative diseases.
Specifically, the biotech is interested in a class of proteins called intrinsically disordered proteins that doesn’t have a single folded structure. MYC, for instance, is a cancer-causing IDP.
They can also range from fully unstructured to partially structured ones containing a disordered region, something condensate players like Dewpoint are focused on.
Virginia Burger, CEO and Founder of New Equilibrium, is a 2020 MassNextGen recipient. The MLSC program is a five year, more than $2 million commitment to ensure greater gender parity in the next generation of life science entrepreneurs.